With the results of ODYSSEY Outcomes and the more attractive pricing for PCSK9 inhibitors, how do you now see the landscape for this therapy, especially in the context of the lipid medicine/atherosclerosis specialist and the preventive cardiologist?
With the results of ODYSSEY Outcomes and the more attractive pricing for PCSK9 inhibitors, how do you now see the landscape for this therapy, especially in the context of the lipid medicine/atherosclerosis specialist and the preventive cardiologist?
Created by
Presenter
Michael Davidson, MD, FACC, FACP, FNLA
Clinical Professor Director of Preventive Cardiology The University of Chicago Hospitals and Clinic Pritzker School of Medicine Chicago, Illinois